Exclusive Summary

• With the originator's core patents fully expired, this classic long-acting Single-Pill Combination (SPC) maintains strong generic substitution and incremental demand in emerging markets such as SE Asia, LATAM, and Africa.
• Targeting over 1.28 billion hypertensive adults globally with an effective control rate of only 21%, this lifelong medication addresses a chronic disease market with massive scalability and rigid demand.
• This classic 40mg:12.5mg dosage is highly recommended by major international guidelines as an optimal initial or synergistic therapy, significantly improving patient adherence through powerful synergistic efficacy.
• Leveraging China's integrated API-to-finished-product supply chain, the product possesses significant economies of scale and cost advantages, making it highly competitive for national tenders and healthcare cost-control policies.
• Offering a Distribution cooperation model supported by comprehensive CTD-format dossiers and stable supply chains, it empowers overseas distributors to swiftly capture out-of-hospital retail and primary care grassroots markets.